2018
Risk factors for pleural effusion recurrence in patients with malignancy
Grosu HB, Molina S, Casal R, Song J, Li L, Diaz‐Mendoza J, Reddy C, Yarmus L, Schiavo D, Simoff M, Johnstun J, Raid A, Feller‐Kopman D, Lee H, Sahetya S, Foley F, Maldonado F, Tian X, Noor L, Miller R, Mudambi L, Saettele T, Vial‐Rodriguez M, Eapen GA, Ost DE. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology 2018, 24: 76-82. PMID: 29966171, PMCID: PMC7315912, DOI: 10.1111/resp.13362.Peer-Reviewed Original ResearchConceptsMalignant pleural effusionRisk factorsFluid recurrenceMetastatic diseasePleural fluidHazards modelRecurrent symptomatic malignant pleural effusionsSymptomatic malignant pleural effusionRetrospective multicentre cohort studyFine-Gray subdistribution hazard modelPleural effusion recurrenceMulticentre cohort studyHazard of recurrenceCause-specific hazards modelPleural fluid cytologyChest X-rayPleural fluid LDHPleural effusion sizeSubdistribution hazard modelEffusion recurrenceFirst thoracentesisSymptom palliationCohort studyCumulative incidencePrimary outcome
2012
The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: A pilot study
Silverman RA, Foley F, Dalipi R, Kline M, Lesser M. The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: A pilot study. Respiratory Medicine 2012, 106: 1096-1102. PMID: 22580235, DOI: 10.1016/j.rmed.2012.04.002.Peer-Reviewed Original ResearchConceptsAcute asthmaSevere acute asthmaSevere asthma episodesUse of rhDNasePrimary study endpointNon-fatal casesPost-randomization time pointsViscoelasticity of sputumBronchodilator therapyIpratropium treatmentPlacebo patientsSymptomatic asthmaticsFatal asthmaAdult asthmaticsClinical improvementMucous pluggingIll adultsStudy endpointStandardized careAsthma episodesEmergency departmentClinical trialsTherapeutic roleMucolytic agentTreatment groups